![]() ![]() Incidence of myocarditis or pericarditis after mRNA vaccination was reported to occur at a rate of one to two cases per 100,000 vaccinated, according to the study. “Although epidemiological reports describe key clinical features associated with myocarditis after vaccination with BNT162b2 or mRNA-1273, here, we provide in-depth immunoprofiling of patients with post-vaccine myocarditis.” Yonker, MD, co-director of the Cystic Fibrosis Center, the Cystic Fibrosis Therapeutic Development Center and the Pulmonary Genetics Clinic at Massachusetts General Hospital and assistant professor of pediatrics at Harvard Medical School, and colleagues wrote. Understanding the immunophenotype associated with mRNA vaccine-induced myocarditis is an essential first step in preventing negative complications resulting from this novel vaccine technology,” Lael M. The immune response driving post-vaccine myocarditis has not yet been elucidated. “ Rarely, some individuals develop myocarditis after mRNA vaccination. In addition, antibody profiling and T-cell responses were similar among patients who developed myocarditis after messenger RNA (mRNA) vaccination compared with those who had mRNA vaccination but did not develop myocarditis, researchers reported in Circulation. Researchers identified the presence of circulating spike protein that evaded antibody recognition in adolescents and young adults who present with myocarditis after SARS-CoV-2 messenger RNA vaccination. If you continue to have this issue please contact to Healio On the other hand, in vitro evidence suggests that spike protein could impair pericyte and endothelial cell function via ACE2 and thus contribute to myocarditis.We were unable to process your request. As myocarditis has also been observed in response to other vaccines, such as vaccines against influenza and smallpox, and non-mRNA vaccines against COVID-19, the circulating spike protein could be a biomarker of immune dysregulation leading to myocarditis, rather than a causal agent of this. It remains unclear if spike protein has a direct role in the pathogenesis of myocarditis furthermore, it was detected in the majority of but not all patients with myocarditis. The most compelling difference in adolescents who developed post-vaccine myocarditis compared with the asymptomatic cohort was the presence of a surprisingly high level of full-length unbound spike protein that remained detectable for up to 3 weeks after vaccination and somehow eluded antibody recognition despite the lack of significant differences between the two groups in antibody production and neutralization capacity. They found that antibody-bound S1 protein could be detected in about 30% of the two cohorts of vaccinated adolescents but in none of the analyzed adults from a separate cohort ( n = 13 >18 years of age) after the second vaccine dose this suggested an age difference in the processing and clearance of the spike protein translated from the mRNA vaccine, which will need to be confirmed with further investigation of a larger number of participants. To identify the potential stimuli for this innate inflammation, the authors used ultra-sensitive single-molecule array antigen assays to detect the levels of spike protein and cleaved spike protein (S1) in free form or bound to antibodies. However, the participants with post-vaccine myocarditis presented a cytokine profile indicative of innate immune cell activation, an increase in neutrophils, and a decrease in platelets compared with the profile of the asymptomatic cohort. ![]() The authors found no difference in the antibody responses (antibody serotypes and function) of the two cohorts or significant differences in T cell responses. The participants included in the study were mostly male (80% of the myocarditis cohort 40% of the control cohort) and mostly between 12 and 21 years of age, and most of the patients developed myocarditis within a week after the second vaccine dose. presented the results of extensive immune profiling of 16 patients hospitalized for myocarditis after mRNA vaccination against COVID-19, compared with that of 45 healthy, asymptomatic, age-matched control participants, at 3 weeks after the second vaccination dose. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |